Eagle Pharmaceuticals Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Eagle Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EGRX, but not buy additional shares or sell existing shares.
View analyst ratings for Eagle Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Eagle Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eagle Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Eagle Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Eagle Pharmaceuticals.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced its quarterly earnings data on Monday, March, 1st. The specialty pharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.42) by $2.38. The specialty pharmaceutical company had revenue of $49.92 million for the quarter, compared to analyst estimates of $50.08 million. Eagle Pharmaceuticals had a net margin of 2.65% and a trailing twelve-month return on equity of 8.50%.
View Eagle Pharmaceuticals' earnings history.

Eagle Pharmaceuticals' stock was trading at $39.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EGRX stock has increased by 13.3% and is now trading at $44.27.
View which stocks have been most impacted by COVID-19.

1 brokerages have issued 12-month price targets for Eagle Pharmaceuticals' stock. Their forecasts range from $46.00 to $46.00. On average, they anticipate Eagle Pharmaceuticals' stock price to reach $46.00 in the next twelve months. This suggests a possible upside of 3.9% from the stock's current price.
View analysts' price targets for Eagle Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Eagle Pharmaceuticals include Prestige Consumer Healthcare (PBH), Dicerna Pharmaceuticals (DRNA), Zentalis Pharmaceuticals (ZNTL), CytoDyn (CYDY), NGM Biopharmaceuticals (NGM), Madrigal Pharmaceuticals (MDGL), Axsome Therapeutics (AXSM), Amarin (AMRN), Revance Therapeutics (RVNC), IGM Biosciences (IGMS), MacroGenics (MGNX), Seres Therapeutics (MCRB), Kura Oncology (KURA), FibroGen (FGEN) and Morphic (MORF).
View all of EGRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Health (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Eagle Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Scout Investments Inc. (1.11%), Pacer Advisors Inc. (0.10%) and State of Alaska Department of Revenue (0.06%). Company insiders that own Eagle Pharmaceuticals stock include Douglas L Braunstein and Hudson Executive Capital Lp.
View institutional ownership trends for Eagle Pharmaceuticals.

EGRX stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue.
View insider buying and selling activity for Eagle Pharmaceuticals or view top insider-selling stocks.

EGRX stock was purchased by a variety of institutional investors in the last quarter, including Scout Investments Inc., and Pacer Advisors Inc..
View insider buying and selling activity for Eagle Pharmaceuticals or or view top insider-buying stocks.

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EGRX stock can currently be purchased for approximately $44.27.

Eagle Pharmaceuticals has a market capitalization of $585.12 million and generates $195.89 million in revenue each year. The specialty pharmaceutical company earns $14.31 million in net income (profit) each year or $1.38 on an earnings per share basis.

Eagle Pharmaceuticals employs 108 workers across the globe.

The official website for Eagle Pharmaceuticals is www.eagleus.com.

Eagle Pharmaceuticals is headquartered at 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677.

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]